Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants
Recommendations
As issued by the authors
The axiom first, do no harm should always be considered; an initial period of observation (watchful waiting) is often appropriate to characterise tumour behaviour
Patients should be referred to specialised high-volume medical centres
Original publication
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol. Published 31 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →